Q-omics provides the consensus-scored RN7SKP160 profile across patient tissues and cancer cell-line models. RN7SKP160 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP160 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, RN7SKP160 RNA expression shows 15,395 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, KIRP, and TGCT as cancer lineages where RN7SKP160 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP160 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP160 survival associations across molecular data types. RN7SKP160 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP160 RNA expression–survival associations across cancer types. High RN7SKP160 expression shows unfavorable associations in LUAD and THCA, but favorable associations in PAAD, UCS, HNSC and KIRP. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RN7SKP160 RNA expression.
This table summarizes RN7SKP160 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP160. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP160 shows lower tumor expression in KIRP, LUSC, COAD, LUAD and THCA and higher tumor expression in KIRC. The KIRP box plot shows higher RN7SKP160 RNA expression in normal versus tumor tissue (log2 FC = −0.402, t-test p = .001).
This table shows molecular features associated with RN7SKP160 in patient tissues and cancer cell lines. In patient samples, RN7SKP160 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
